Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE5A | O76074 | 5/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 5/20 | 1.00 |
| ▸ | PDE11A | Q9HCR9 | 5/20 | 1.00 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 1.00 |
| ▸ | PDE2A | O00408 | 4/20 | 1.00 |
| ▸ | PDE8A | O60658 | 4/20 | 1.00 |
| ▸ | PDE9A | O76083 | 3/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16899893 | 1.00 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL4920045 | 0.98 | PDE4A (0.97) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL19159222 | 0.98 | PDE4A (0.95) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL10201367 | 0.92 | PDE4A (0.86) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL773887 | 0.92 | PDE4A (0.84) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL4920743 | 0.91 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL19134017 | 0.91 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8046132 | 0.91 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8245508 | 0.91 | PDE4A (0.83) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8046139 | 0.90 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091983-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A PDE-1 INHIBITOR AND A PDE-2 INHIBITOR | INTRA CELLULAR THERAPIES INC (US) | 2019-10-02 | — | — | EP | claimed |
| US-9849132-B2 | Products and pharmaceutical compositions | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-12-26 | — | — | US | claimed |
| US-9624230-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-04-18 | — | — | US | claimed |
| US-20160324860-A1 | PRODUCTS AND PHARMACEUTICAL COMPOSITIONS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-10 | — | — | US | claimed |
| US-8273750-B2 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | claimed |
| US-11839614-B2 | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839614-B2 | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230355625-A1 | METHODS OF TREATMENT | INTRA-CELLULAR THERAPIES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355625-A1 | METHODS OF TREATMENT | INTRA-CELLULAR THERAPIES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11759465-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20100273754-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2010098839-A1 | PDE 1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2009075784-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | INTRA-CELLULAR THERAPIES, INC (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | INTRA-CELLULAR THERAPIES, INC (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2006133261-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355625-A1 | METHODS OF TREATMENT | PDE1A, PDE1B, PDE7A | PDE4A 4/4885PDE5A 11/4885PDE3B 18/4885 |
| US-20100273754-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE5A 406/4885PDE3B 165/4885 |
| US-11839614-B2 | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression | ADORA2A, ADORA1, ADORA2B | PDE4A 17/4885PDE5A 26/4885PDE3B 32/4885 |
| US-20100087450-A1 | ORGANIC COMPOUNDS | PDE3A, PDE5A, PDE2A | PDE4A 8/4885PDE5A 2/4885PDE3B 4/4885 |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | PDE9A, PDE3A, PDE7A | PDE4A 8/4885PDE5A 5/4885PDE3B 7/4885 |
| US-20160324860-A1 | PRODUCTS AND PHARMACEUTICAL COMPOSITIONS | PDE2A, PDE3A, PDE5A | PDE4A 6/4885PDE5A 3/4885PDE3B 4/4885 |
| US-20230338385-A1 | NOVEL USES | ADORA2A, ATP2A1, ADORA2B | PDE4A 11/4885PDE5A 14/4885PDE3B 21/4885 |
| US-11759465-B2 | Uses | ADORA2A, ADORA2B, ADORA1 | PDE4A 12/4885PDE5A 15/4885PDE3B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.